X-Linked Retinoschisis (XLRS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

X-Linked Retinoschisis Emerging Therapy and TPP Insights

Thelansis's "X-Linked Retinoschisis (XLRS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

X-Linked Retinoschisis Overview

X-linked retinoschisis (XLRS) is a rare inherited retinal disorder caused by pathogenic variants in RS1, which encodes retinoschisin, a protein essential for retinal cell adhesion and organization. It primarily affects males and typically presents in childhood with bilateral macular involvement, reduced visual acuity, and splitting of retinal layers. Vision may decline during childhood, although progression varies; vitreous hemorrhage and retinal detachment can occur in some patients. Management includes regular retinal monitoring, correction of refractive errors, low-vision support, and surgery for selected complications. Carbonic anhydrase inhibitors may reduce retinal schisis cavities in some patients, although improvements in visual function are variable. No disease-specific therapy is currently approved. ATSN-201, an investigational gene therapy developed by Atsena Therapeutics, is undergoing pivotal Phase 3 evaluation. Early sponsor-reported results suggest improvements in retinal structure and visual function, but confirmation in controlled trials is needed.

Key Highlights

• In the United States, diagnosed XLRS cases are estimated at 19,598 in 2026.
• X-linked Retinoschisis (XLRS) is an inherited retinal disorder that primarily affects males and can cause progressive vision impairment.
• Retinal complications can significantly affect visual function and quality of life.
• Unmet need remains for treatments that preserve vision and address the underlying genetic cause.

Market Overview

• The Spain XLRS market is projected to grow from $3M in 2026 to $28M by 2036.
• Market growth is driven by:
• Advances in gene therapy and other emerging retinal treatments
• Progress in genetic diagnosis and clinical research
• Future growth will depend on therapies that demonstrate meaningful and durable improvements in visual outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country